Barclays raises Iovance Biotherapeutics price target to $15
Barclays maintained an Overweight rating on Iovance Biotherapeutics and raised its price target to $15.00 from $13.00, per Benzinga ratings action.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.